CSPC Innovation Pharmaceutical Co., Ltd. Class A

CSPC Innovation Pharmaceutical Co., Ltd. Class A

SSZSE:300765
32.22
CNY
-0.46
(-1.41%)
0.85EPS
66.19P/E
66.28BMarket Cap
Mar 12Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.74
0.84
1.01
1.17
1.4
1.14
1.12
1.38
1.96
1.82
1.42
1.55
3.26
Basic EPS, GAAP
0.12
0.13
0.23
0.22
0.25
0.25
0.25
0.29
0.54
0.31
0.04
-0.17
0.71
Free Cash Flow per Basic Share
0.1
0.07
-0.01
-0.05
0.11
0.19
0.2
0.07
0.39
0.1
-1.22
-0.55
- -
Dividend per Share
- -
- -
0.06
0.03
- -
- -
0.02
0.03
0.06
0.07
0.27
0.03
0.01
Book Value per Share
0.61
0.71
0.65
0.87
1.12
2.04
2.27
2.79
2.94
3.76
2.66
1.9
2.77
Tangible Book Value per Share
0.54
0.65
0.57
0.8
1.05
1.99
2.22
2.74
2.91
3.59
2.5
1.74
2.62
Basic Weighted Avg Shares
885
885
883
884
886
1,105
1,180
1,337
1,337
1,397
1,399
1,393
1,393
Sales/Revenue/Turnover
651
742
890
1,031
1,240
1,257
1,317
1,850
2,626
2,539
1,981
2,158
4,541
Operating Margin (%)
19.41
17.75
24.63
24.1
22.21
24.23
26.02
24.82
28.92
6.88
-13.17
-24.89
28.34
Depreciation Expense
21
25
27
35
43
47
53
69
73
156
217
223
- -
Net Income, GAAP
108
116
207
195
224
273
300
393
726
434
54
-241
993
Effective Tax Rate (%)
14.83
15.64
16.85
18.39
19.22
18.39
17.94
17.84
14.65
52.06
- -
- -
2.74
Profit Margin (%)
16.63
15.58
23.2
18.9
18.05
21.74
22.76
21.26
27.65
17.11
2.71
-11.18
21.86
Working Capital
240
389
33
192
312
1,536
1,678
2,079
2,608
2,714
1,368
144
1,536
LT Debt
- -
120
- -
50
- -
- -
1
- -
20
1
- -
2
245
Total Equity
537
627
572
767
999
2,415
2,687
3,298
3,944
5,483
4,496
2,795
4,294
Return on Invested Capital (%)
- -
17.71
28.27
24.97
22.9
15.48
11.55
13.36
20.06
2.65
- -
- -
25.38
Return on Capital (%)
- -
17.48
29.12
25.42
23.4
15.73
11.75
13.16
20
15.73
- -
- -
17.95
Return on Common Equity (%)
- -
19.89
34.52
29.11
25.47
16.08
11.79
13.18
20.1
9.43
1.19
-7.54
26.14

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1
537
547
LT Borrowings
10
250
244
LT Finance Leases
2
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,405
1,405
1,405
Market Capitalization
44,610
38,247
66,283

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,770
5,482
4,967
Cash, Cash Equivalents & STI
979
3,798
2,463
Accounts Receivable, Net
598
459
646
Inventories
457
414
377
Total Current Liabilities
2,772
3,875
3,431
Payables & Accruals
- -
- -
- -
ST Debt
1
537
547
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
23.41%
5.1%
-37.83%
Free Cash Flow
-111.51%
-213.64%
-55.39%
Net Income, GAAP
-44.11%
-112.15%
-548.8%
Sales/Revenue/Turnover
12.82%
13.2%
8.93%
Total Cash Common Dividend
486.81%
71.35%
-90.26%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
524
448
507
502
1,981
2025
472
578
- -
565
2,158
2026
665
2,576
736
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.07
0.04
- -
-0.06
0.04
2025
-0.02
0.02
- -
-0.16
-0.17
2026
-0.07
0.97
-0.04
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.27
2025
- -
- -
- -
0.01
0.03
2026
- -
- -
- -
- -
- -

Company Description

CEO
Bing Yao
Full Time Employees
2,369
Sector
Consumer non-durables
Industry
Food: major diversified
Address
No. 36, Fuqiang Western Road Shijiazhuang HE China 051430
IPO Date
Mar 22, 2019
Business
CSPC Innovation Pharmaceutical Co., Ltd. operates as a wholly-owned subsidiary of CSPC Pharmaceutical Group, focusing on the production and sale of functional food ingredients and innovative pharmaceutical products. The company specializes in manufacturing two core product lines: chemically synthesized caffeine used as a food additive and vitamin C lozenges, offering a comprehensive product structure to meet diverse consumer needs within China’s functional food industry. CSPC Innovation has developed a significant brand advantage and product depth, positioning itself as a major global production base for synthetic caffeine. Founded in 1997 and headquartered in Shijiazhuang, China, the company leverages extensive research and development capabilities as part of the broader CSPC Group's pharmaceutical operations. Recent major developments include its transition towards becoming a core innovative drug platform within CSPC Group through strategic acquisitions and expansions. Notably, in 2025, CSPC Innovation undertook the acquisition of an additional 29% stake in Jushi Biologics for RMB 1.1 billion, increasing ownership to 80%, thereby strengthening its pipeline focused on antibody-drug conjugates, monoclonal antibodies, and mRNA vaccines. Jushi Biologics launched lead products such as enlonstobart and omalizumab in 2024, enhancing the group’s biologics offerings and innovation profile. The company also participates actively in licensing deals and fundraising efforts to support product development and expansion, aligning with CSPC Group’s broader strategic push into innovative drug development and global market growth. The company operates within the pharmaceutical and functional food industry sectors, targeting both domestic Chinese markets and over 100 countries internationally through export sales. Its operations are supported by CSPC's extensive R&D network, including centers in China, the United States, and other strategic locations. CSPC Innovation's growth strategy encompasses deepening its product portfolio in functional food additives while expanding into high-technology pharmaceuticals through research collaborations, acquisitions, and increased clinical trial activity. This strategy reflects a clear shift aiming to enhance its presence in both nutritional and therapeutic product markets, underpinned by robust innovation and internationalization efforts.